Valeant Includes OTCs In Bid For Dramatic Growth By 2013
This article was originally published in The Tan Sheet
Executive Summary
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.
You may also be interested in...
Bausch + Lomb Buy Vaults Valeant Into Consumer Eye Care Space
Bausch + Lomb retains its name and becomes a division of Valeant in the $8.7 billion acquisition expected to close in the 2013 third quarter.
Bausch + Lomb Buy Vaults Valeant Into Consumer Eye Care Space
Bausch + Lomb retains its name and becomes a division of Valeant in the $8.7 billion acquisition expected to close in the 2013 third quarter.
Valeant’s OTC Pickups Emphasize Specialty Segments, Growth Markets
The Montreal pharma company includes a focus on OTCs and generics in its quest to grow while remaining relatively immune to patent cliffs and scaled-back Rx reimbursements. Valeant’s recent PEDiNOL Pharmacal acquisition, including OTC podiatry products, fits into its niche category strategy.